EGFR and non-small cell lung carcinoma: Meanwhile, about 10% of the EGFR-mutant NSCLC patients harbor uncommon mutations (EGFR mutations except for L858R point mutation and exon 19 deletion) and the effectiveness of first-line EGFR-TKIs in these patients remain controversial [3–6].